# Navnath S Gavande

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3550900/publications.pdf

Version: 2024-02-01

| 45 | 1,147 | 471509 17 | 501196 28 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 49 | 49 | 49 | 1964 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | DNA repair targeted therapy: The past or future of cancer treatment?. , 2016, 160, 65-83. | | 307 |
| 2 | Modulating DNA Repair Pathways to Improve Precision Genome Engineering. ACS Chemical Biology, 2018, 13, 389-396. | 3.4 | 99 |
| 3 | 7-Hydroxy-benzopyran-4-one Derivatives: A Novel Pharmacophore of Peroxisome Proliferator-Activated Receptor Î± and -Î³ (PPARÎ± and Î³) Dual Agonists. Journal of Medicinal Chemistry, 2009, 52, 6835-6850. | 6.4 | 83 |
| 4 | Regulation of Lowâ€Density Lipoprotein Receptor and 3â€Hydroxyâ€3â€Methylglutaryl Coenzyme A Reductase Expression by Zingiber officinale in the Liver of Highâ€Fat Dietâ€Fed Rats. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 389-395. | 2.5 | 56 |
| 5 | The enantiomers of syn-2,3-difluoro-4-aminobutyric acid elicit opposite responses at the GABA<sub>C</sub>receptor. Chemical Communications, 2012, 48, 829-831. | 4.1 | 51 |
| 6 | 2â€²â€Methoxyâ€6â€methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA<sub>A</sub> receptors. British Journal of Pharmacology, 2012, 165, 880-896. | 5.4 | 44 |
| 7 | Medicinal chemistry of Ï•GABA<sub>C</sub> receptors. Future Medicinal Chemistry, 2011, 3, 197-209. | 2.3 | 41 |
| 8 | 3-Hydroxy-2â€²-methoxy-6-methylflavone: A potent anxiolytic with a unique selectivity profile at GABAA receptor subtypes. Biochemical Pharmacology, 2011, 82, 1971-1983. | 4.4 | 37 |
| 9 | Structure-Based Design of Highly Selective Î²-Secretase Inhibitors: Synthesis, Biological Evaluation, and Proteinâ€“Ligand X-ray Crystal Structure. Journal of Medicinal Chemistry, 2012, 55, 9195-9207. | 6.4 | 36 |
| 10 | Agonist responses of (R)- and (S)-3-fluoro-Î³-aminobutyric acids suggest an enantiomeric fold for GABA binding to GABAC receptors. Chemical Communications, 2011, 47, 7956. | 4.1 | 32 |
| 11 | Insights into the Mechanism of Inhibition of CXCR4: Identification of Piperidinylethanamine Analogs as Anti-HIV-1 Inhibitors. Antimicrobial Agents and Chemotherapy, 2015, 59, 1895-1904. | 3.2 | 28 |
| 12 | Novel Cyclic Phosphinic Acids as GABA<sub>C</sub> Ï•Receptor Antagonists: Design, Synthesis, and Pharmacology. ACS Medicinal Chemistry Letters, 2011, 2, 11-16. | 2.8 | 27 |
| 13 | The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists. Bioorganic and Medicinal Chemistry, 2013, 21, 766-778. | 3.0 | 24 |
| 14 | Guanidino Acids Act as Ï•1 GABAC Receptor Antagonists. Neurochemical Research, 2009, 34, 1704-1711. | 3.3 | 22 |
| 15 | Design, Synthesis, and Pharmacological Evaluation of Fluorescent and Biotinylated Antagonists of Ï<sub>1</sub> GABA<sub>C</sub> Receptors. ACS Medicinal Chemistry Letters, 2013, 4, 402-407. | 2.8 | 22 |
| 16 | Identification of Benzopyranâ€4â€one Derivatives (Isoflavones) as Positive Modulators of GABA<sub>A</sub> Receptors. ChemMedChem, 2011, 6, 1340-1346. | 3.2 | 19 |
| 17 | Discovery and development of novel DNA-PK inhibitors by targeting the unique Kuâ€“DNA interaction. Nucleic Acids Research, 2020, 48, 11536-11550. | 14.5 | 19 |
| 18 | Characterization of a Drosophila Ortholog of the Cdc7 Kinase. Journal of Biological Chemistry, 2015, 290, 1332-1347. | 3.4 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The flavonoid, 2â€²-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1266-1282. | 4.3 | 18 |
| 20 | Pro-inflammatory cytokines and chemokines initiate multiple prostate cancer biologic pathways of cellular proliferation, heterogeneity and metastasis in a racially diverse population and underlie the genetic/biologic mechanism of racial disparity: Update. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 34-40. | 1.6 | 18 |
| 21 | Design, synthesis, biological evaluation of 3,5-diaryl-4,5-dihydro-1H-pyrazole carbaldehydes as non-purine xanthine oxidase inhibitors: Tracing the anticancer mechanism via xanthine oxidase inhibition. Bioorganic Chemistry, 2021, 107, 104620. | 4.1 | 18 |
| 22 | Microwave-enhanced synthesis of 2,3,6-trisubstituted pyridazines: application to four-step synthesis of gabazine (SR-95531). Organic and Biomolecular Chemistry, 2010, 8, 4131. | 2.8 | 16 |
| 23 | Structure-Guided Optimization of Replication Protein A (RPA)â€“DNA Interaction Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 1118-1124. | 2.8 | 16 |
| 24 | Ph2S2â€“CaH2 in N-methyl-2-pyrrolidone as an efficient protocol for chemoselective cleavage of aryl alkyl ethers. Tetrahedron, 2006, 62, 4201-4204. | 1.9 | 13 |
| 25 | Structurally Diverse GABA Antagonists Interact Differently with Open and Closed Conformational States of the Ï<sub>1</sub> Receptor. ACS Chemical Neuroscience, 2012, 3, 293-301. | 3.5 | 13 |
| 26 | Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Proteinâ€“DNA Interaction. Journal of Medicinal Chemistry, 2017, 60, 8055-8070. | 6.4 | 12 |
| 27 | Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair. Frontiers in Oncology, 2022, 12, 850883. | 2.8 | 12 |
| 28 | Antidepressant, anticonvulsant and antinociceptive effects of 3â€²-methoxy-6-methylflavone and 3â€²-hydroxy-6-methylflavone may involve GABAergic mechanisms. Pharmacological Reports, 2017, 69, 1014-1020. | 3.3 | 11 |
| 29 | Differentiating Enantioselective Actions of GABOB: A Possible Role for Threonine 244 in the Binding Site of GABA<sub>C</sub> Ï<sub>1</sub> Receptors. ACS Chemical Neuroscience, 2012, 3, 665-673. | 3.5 | 8 |
| 30 | Natural Products as an Emerging Therapeutic Alternative in the Treatment of Neurological Disorders. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-2. | 1.2 | 6 |
| 31 | In Vivo Targeting Replication Protein A for Cancer Therapy. Frontiers in Oncology, 2022, 12, 826655. | 2.8 | 6 |
| 32 | Targeting the nucleotide excision repair pathway for therapeutic applications. , 2016, , 135-150. | | 4 |
| 33 | Implications of the USP10-HDAC6 axis in lung cancer - A path to precision medicine. , 2021, 2, . | | 2 |
| 34 | Abstract 2829: Targeting the DNA damage response and DNA-PK signaling via small molecule Ku inhibitors. , 2018, , . | | 2 |
| 35 | Nanomedicine for overcoming therapeutic and diagnostic challenges associated with pancreatic cancer. Drug Discovery Today, 2022, , . | 6.4 | 1 |
| 36 | Abstract PO-023: Impact of a novel Ku-DNA binding inhibitor on the IR-induced DNA damage response. , 2021, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Abstract C57: Discovery and development of replication protein A (RPA)-DNA interaction inhibitors for cancer chemotherapy. , 2015, , . | | 0 |
| 38 | Abstract C58: Small molecule inhibitors targeting the interaction of xeroderma pigmentosum group A protein with cisplatin-damaged DNA. , 2015, , . | | 0 |
| 39 | Abstract B34: Development of novel small molecule inhibitors targeting DNA repair proteins. , 2017, , . | | 0 |
| 40 | Abstract LB-119: Targeting DNA-PK via small molecule inhibitors of the Ku-DNA interaction. , 2017, , . | | 0 |
| 41 | Abstract 1416: Development of small molecule inhibitors for cancer therapy by targeting RPA and XPA nucleotide excision repair proteins. , 2017, , . | | 0 |
| 42 | Abstract LB-A11: Targeting DNA-PK and the DNA damage response via small molecule Ku inhibitors. , 2018, , . | | 0 |
| 43 | Abstract 1301: Targeting protein-DNA interactions in the DNA damage response: Lead identification and optimization for novel inhibitors of RPA and Ku. , 2019, , . | | 0 |
| 44 | Abstract A095: Targeting protein-DNA interactions in the DNA damage response: Lead identification and optimization for novel inhibitors of RPA and Ku. , 2019, , . | | 0 |
| 45 | Abstract 1301: Targeting protein-DNA interactions in the DNA damage response: Lead identification and optimization for novel inhibitors of RPA and Ku. , 2019, , . | | 0 |